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Background: Chronic obstructive pulmonary disease (COPD) is frequent and often coexists with other diseases. The
aim of this study was to quantify the prevalence of COPD and related chronic comorbidity among patients aged
over 40 years visiting family practices in an area of Madrid.
Methods: An observational, descriptive, cross-sectional study was conducted in a health area of the Madrid
Autonomous Region (Comunidad Autónoma de Madrid). The practice population totalled 198,670 persons attended
by 129 Family Physicians (FPs), and the study population was made up of persons over the age of 40 years drawn
from this practice population. Patients were deemed to have COPD if this diagnosis appeared on their clinical
histories. Prevalence of COPD; prevalence of a further 25 chronic diseases in patients with COPD; and standardised
prevalence ratios, were calculated.
Results: Prevalence of COPD in family medicine was 3.2% (95% CI 3.0–3.3) overall, 5.3% among men and 1.4%
among women; 90% of patients presented with comorbidity, with a mean of 4 ± 2.04 chronic diseases per patient,
with the most prevalent related diseases being arterial hypertension (52%), disorders of lipid metabolism (34%),
obesity (25%), diabetes (20%) and arrhythmia (15%). After controlling for age and sex, the observed prevalence of
the following ten chronic diseases was higher than expected: heart failure; chronic liver disease; asthma; generalised
artherosclerosis; osteoporosis; ischaemic heart disease; thyroid disease; anxiety/depression; arrhythmia; and obesity.
Conclusions: Patients with COPD, who are frequent in family practice, have a complex profile and pose a clinical
and organisational challenge to FPs.
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Chronic obstructive pulmonary disease (COPD) is fre-
quent, incapacitating at advanced stages, leads to the
death of the patient and, by 2030, is expected to be the
fourth leading cause of death and the seventh leading
cause of loss of disability adjusted life years (DALYs) [1].
Until the year 2000, few epidemiological studies had
addressed COPD, and those that were undertaken
mostly targeted the population aged over 40 years. A* Correspondence: lgarcia.gapm02@salud.madrid.org
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distribution, and reproduction in any mediummeta-analysis of studies published up to 2004 estimated
COPD prevalence among over 40-year-olds to be 10%
[2]; however, heterogeneity in the definition of case
makes difficult results comparison. Latest estimations in
Spain, using the GOLD criteria, set COPD prevalence in
10.2%, with strong variation among different regions and
an important fall regarding a previous study performed
ten years earlier [3].
Comorbidity is present in one third of the adult popu-
lation and its prevalence increases with age, eventually
affecting 60% of the population aged 55 to 74 years [4];
moreover, it has been observed that certain chronic dis-
eases tend to be present in clusters [5].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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related comorbidity is a key prognostic factor of the con-
sequences of COPD. Some of these diseases occur
regardless of COPD, some are related by virtue of having
a common cause(s), and others share risk factors [6]. For
instance, inflammation brought about by smoking can
be a common route for a series of diseases, such as is-
chaemic heart disease, heart failure, osteoporosis, an-
aemia, cancer, depression and diabetes [7]. COPD
associated comorbidity contributes to symptoms, deter-
mines the quality of life [8,9], increments healthcare
costs [10] and increments the mortality of patients suf-
fering it [11].
Clinical research targets isolated diseases. Chronic care
is geared to managing individual diseases (disease man-
agement programmes), and the clinical practice guide-
lines that underpin these models likewise focus on
isolated diseases [12]. Stratification of COPD patients
takes into account the level of obstruction, but does
not consider the burden of comorbidity, notwith-
standing its implications.
Research into comorbidity is scant, and relatively new:
there are population studies, hospital studies and pri-
mary healthcare studies. Most of these studies have ana-
lyzed the association between COPD and several
isolated diseases; and a few of them have analyzed its as-
sociation to larger groups of chronic diseases; however
the strong differences between diseases from the two
groups make their comparison difficult. COPD is a dis-
ease suffered by elder people and several associated dis-
eases are frequent for their high prevalence among elder
population; as a consequence a key point when studying
comorbidity is to distinguish clearly if these diseases are
independent or if they are associated more frequently
than in general population [13].
The aim of this study was to quantify the prevalence
of COPD, and quantify and describe diagnosed COPD-
related chronic comorbidity in family practices in an
area of Madrid, using EMR-based data.
Methods
We conducted an observational, descriptive, cross-
sectional study in a health area of the Madrid
Autonomous Region (Comunidad de Madrid), based
on a catchment population of 887,134 and data per-
taining to 2007.
The study used the EMRs of 198,670 persons, corre-
sponding to the practice population allocated to 129 FPs
who, by way of inclusion criteria, met the following two
EMR utilization quality requirements: 1) annotations in
over 64% of medical visits (75th percentile); and 2) a
mean of more than four care episodes per patient.
Data were drawn from clinical histories. The follow-
ing data were extracted from each patient: age; sex;and all diagnoses, grouped into Expanded Diagnosis
Clusters (EDC), for which medical advice had been
sought in 2007.
Patients were classified by means of the ACGW Case–
Mix System, version 7, developed by Johns Hopkins Uni-
versity [14] on the premise that the level of resources
needed for health care is related to disease burden. This
system enables mutually exclusive groups of patients,
Adjusted Clinical Groups (ACGs), to be formed on the
basis of the criterion of similar use of resources, using
age, sex and morbidity across a given period of time
(usually one year) for the purpose. In addition, patients
can be regrouped, according to their respective ACGs,
into six Resource Utilisation Bands (RUBs), which are
based on expected use and range from zero (RUB 0) to
very high expected use (RUB 5). Furthermore, the system
also generates categories, known as Expanded Diagnosis
Clusters (EDCs), which group patients by reference to
clinical criteria. The ACG W Case – Mix System has been
widely used and has proved its validity to study morbidity
and comorbidity [15-18].
Using pre-established criteria [19], the research team
made an initial selection of 40 chronic EDCs and, in a
second stage, identified 26 so-called: “high prevalence–
high impact” (HP/HI) [16] EDCs, which met one or both
of the following criteria: 1) prevalence above the 50th
percentile; and/or 2) over 50% of patients included in
RUBs 4 and 5 (elevated use of resources). We included
COPD in this list of 26 EDCs, and analysed its associ-
ation with the other 25 high prevalence - high impact
chronic EDCs.
As a first step and using health records patients older
than 40 and suffering EDC RES04 were selected. EDC
RES04 includes emphysema, chronic bronchitis and
COPD. Using this criterion for case definition, the
prevalence of COPD seen in family practices was then
calculated with its 95% confidence level (95% CI).
All statistical analyses were performed using the SPSS
statistical package, version 15.0. In the case of qualitative
variables, frequency distributions were calculated, along
with their 95% CIs where pertinent; in the case of quan-
titative variables, means and their standard deviations
were calculated, normality was tested, and parametric or
non-parametric tests were applied, depending on the
distribution of the variable.
Presence of comorbidity was analysed, by quantifying
the proportion of patients included in each of the desig-
nated 6 comorbidity levels, ranging from isolated COPD
to COPD associated with 5 or more comorbidities. The
association between COPD and each of the 25 HP/HI
diseases studied was quantified, and standardised preva-
lence ratios (observed/expected prevalence) were calcu-
lated, assuming independence between the diseases
analysed and COPD. For the calculation of expected
Table 2 Comorbidity levels in patients with COPD
Comorbidity Men Women Total
N (%) N (%) N (%)
COPD alone 242 (10.19) 46 (6.15) 288 (9.22)
COPD + 1 or more 2134 (89.81) 702 (93.85) 2836 (90.78)
COPD + 2 or more 1706 (71.80) 593 (79.28) 2299 (73.59)
COPD + 3 or more 1262 (53.11) 452 (60.43) 1714 (54.87)
COPD + 4 or more 829 (34.89) 293 (39.17) 1122 (35.92)
COPD + 5 or more 505 (21.25) 164 (21.93) 669 (21.41)
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direct method.
The study was approved by the Ethics Committee of
the Puerta de Hierro University Teaching Hospital.
Results
The 129 FPs covered by the study attended a total prac-
tice population of 198,670 patients, made up of 104,003
women (52.35%) and 94,667 men (47.65%). Of the 3,183
patients diagnosed with COPD, 3,124 (98%) were aged
40 years or over, comprising 2,376 (76%) men and 748
(24%) women. Patients’ mean age was 71.41 ± 11.50 years,
without significant differences between the sexes. COPD
prevalence in the family practices targeted was 3.2%
(95% CI 3.0 – 3.3), and was higher in men than in
women (5.3% vs. 1.4%), a difference of 3.9%, p < 0.01.
COPD patients are a population with an elevated
comorbidity. They have a mean of 4 ± 2.04 chronic HP/
HI diseases. The number of diseases was higher in
women than in men (Mann–Whitney U-test, p < 0.01)
and rose with age (Table 1). Only 9% of patients had iso-
lated COPD, and over half had three or more chronic
problems in addition to COPD (Table 2). Table 3 shows
the percentage distribution of the 25 chronic diseases
studied among COPD patients, overall and by sex: 52%
of patients presented with arterial hypertension, 34%
with lipid metabolism disorders, 25% with obesity,
20% with diabetes, 15% with arrhythmia and 14%
with thyroid disease. Men had more ischaemic heart
disease, generalised artherosclerosis, diabetes mellitus,
chronic liver disease, malignant neoplasms and
chronic renal failure (p < 0.01). Women suffered more
from asthma, arterial hypertension, osteoporosis, thy-
roid disease, degenerative joint disease and anxiety/
depression (p < 0.01).
To control for the effect of age, Table 4 shows
observed and expected prevalences adjusted for age and
sex. In COPD patients, ten of the 25 diseases studied
were more frequent than would have been expected, and
the following were particularly noteworthy, with con-
gestive heart failure being 2.4 times, chronic liver disease
89%, asthma 73%, generalised artherosclerosis 67%,
osteoporosis 42% and ischaemic heart disease 41% more
frequent. The remaining fifteen studied diseases presentTable 1 Chronic diseases / Patient
Age (years) Men Women Total
40 – 49 2.47 ± 1.44 2.42 ± 1.25 2.45 ± 1.37
50 – 59 2.88 ± 1.57 3.23 ± 1.52 2.96 ± 1.56
60 – 69 3.41 ± 1.82 3.94 ± 1.80 3.52 ± 1.83
70 – 79 4.25 ± 2.11 4.50 ± 1.96 4.30 ± 2.09
80 and over 4.55 ± 2.06 4.76 ± 1.96 4.61 ± 2.03
Total 3.93 ± 2.06 4.17 ± 1.97 3.99 ± 2.04no meaningful differences in prevalence with respect to
those found in general population even though some of
them are very frequent among patients suffering COPD.
Discussion
COPD is a disease that affects 3.2% of the population
attended by FPs; 90% of patients had one or more
related diseases and 55% presented with three or more
additional chronic diseases.
The morbidity seen in primary health care comes close
to that reported in population-based studies. In a health
care system such as Spain’s, citizens are not only
required to register with a FP, but, in order to be eligible
for hospital care, must first consult their FP.
In recently published population-based epidemio-
logical study conducted in Spain, COPD prevalence was
estimated at 10.2%. It is well known that COPD tends to
be underdiagnosed by FPs [20-22]. In our case a preva-
lence of 3.2% falls in the range found by Halbert [2] in
the studies that used respiratory symptoms based med-
ical diagnosis as case definition. Comparing to the
prevalence data from the previously referenced study [3]
which used GOLD criteria as case definition, family doc-
tors might have been underdiagnosing 69% of the
patient’s population suffering COPD. This is a high
underdiagnosis ratio, comparable with that of previous
studies, and it has scarcely changed in the last ten years.
At the date of our study, all health centres were sup-
plied with spirometers but FPs are widely known to
make little use of this particular diagnostic technique
[23-25]. Furthermore, underdiagnosis may also be influ-
enced by FPs’ attitude to this disease: indeed, reluctance
to label the patient is such that treatment may even be
initiated before the formal diagnosis has been entered
on the clinical record [26].
Of the total, only 9% of patients presented with COPD
alone, and the remainder tended to have a mean of four
of the 25 chronic diseases studied. Being an aged popu-
lation, the diseases or conditions involved are not only
specific to older persons, but are also present at a fre-
quency that is higher than expected, e.g., heart failure,
arrhythmia, ischaemic heart disease, anxiety/depression,
Table 3 Prevalence of chronic diseases in patients with COPD
EDC Prevalence Men Prevalence Women Prevalence Total
Arterial hypertension 49.96 58.42 51.98
Disorders of lipid metabolism 34.22 35.16 34.44
Obesity 24.66 27.41 25.32
Diabetes mellitus 22.26 16.04 20.77
Anxiety/Depression 16.58 31.68 20.20
Cardiac arrhythmia 15.99 15.24 15.81
Thyroid disease 10.94 24.60 14.21
Malignant neoplasms 14.56 7.62 12.90
Generalised atherosclerosis 12.46 4.14 10.47
Ischaemic heart disease 9.30 5.75 8.45
Deafness, hearing loss 7.74 9.63 8.19
Congestive heart failure 7.70 9.09 8.03
Cerebrovascular disease 7.91 6.15 7.49
Osteoporosis 2.65 20.72 6.98
Chronic renal failure 7.11 3.88 6.34
Asthma 3.75 12.43 5.83
Degenerative joint disease 4.08 10.70 5.67
Glaucoma 4.97 6.42 5.31
Chronic liver disease 5.72 2.67 4.99
Chronic skin ulcer 2.36 2.41 2.37
Cardiac valve disease 2.31 1.87 2.21
Dementias 1.85 2.14 1.92
Parkinson’s disease 1.73 1.47 1.66
Schizophrenia 1.09 1.34 1.15
Benign prostatic hypertrophy 20.71
EDC: expanded diagnosis cluster.
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ised artherosclerosis and chronic liver disease. Smoking-
related inflammation is postulated as a possible cause of
many of these diseases [7].
While other studies have addressed the problem of
comorbidity in patients with COPD, most have focused
on a few isolated diseases. We, in contrast, studied the
association between COPD and a further 25 chronic dis-
eases. We found three studies which analysed the associ-
ation between COPD and a long list of diseases in
primary care patients but, as in the case of other comor-
bidity studies, comparison was hindered by methodo-
logical differences, in that two were based on data from
ongoing records kept by volunteer physicians [27,28]
and the third used data drawn from EMRs [29]. All three
used the same case definition as ours, namely, COPD
recorded by a FP. Results were controlled for age in only
one study [27]. Although the disease list used was not
the same throughout, there was a substantial core group
of diseases that was common to all the studies, including
ours. As in our case, the other three studies alsoobserved a high prevalence of cardiovascular diseases
and osteoporosis.
COPD patients who also present with cardiovascular
diseases register more episodes of COPD exacerbation,
more hospital admissions, a notable increase in cost of
medical care [30] and higher cardiovascular disease mor-
tality [31]. In our case, 16% of patients presented with
arrhythmia, 8.5% with ischaemic heart disease, and a
further 8% with heart failure. This association has been
reported in other studies [32]. In a study focusing on
family practices in Spain, de Miguel found that
prevalence of heart disease among COPD patients
was 19% [8].
As reported by most studies [8,32-34], cardiovascular
risk factors, such as arterial hypertension, lipid metabol-
ism disorders, diabetes and obesity, are among the most
prevalent diseases in COPD patients. This, however, is
due to the ageing of patients, since, once age had been
controlled for, prevalence did not prove very different to
what might have been expected (Table 4). This finding
indicates that, when studying the association between
Table 4 Standardised prevalence of chronic diseases in patients with COPD
EDC Observed prevalence Expected prevalence SPR* Lower
CI
Upper
CI% COPD % COPD
Congestive heart failure 8.03 3.34 2.41 1.88 2.93
Chronic liver disease 4.99 2.63 1.89 1.37 2.42
Asthma 5.83 3.36 1.73 1.29 2.18
Generalised atherosclerosis 10.47 6.25 1.67 1.35 1.99
Osteoporosis 6.98 4.91 1.42 1.09 1.75
Ischaemic heart disease 8.45 6.00 1.41 1.11 1.71
Schizophrenia 1.15 0.85 1.35 0.57 2.12
Thyroid disease 14.21 11.06 1.28 1.07 1.50
Chronic renal failure 6.34 4.96 1.28 0.96 1.59
Anxiety/Depression 20.20 15.86 1.27 1.10 1.45
Cardiac valve disease 2.21 1.76 1.25 0.73 1.77
Cardiac arrhythmia 15.81 12.70 1.25 1.05 1.44
Obesity 25.32 20.49 1.24 1.08 1.39
Chronic skin ulcer 2.37 1.96 1.20 0.72 1.69
Glaucoma 5.31 4.51 1.18 0.86 1.46
Cerebrovascular disease 7.49 6.48 1.16 0.89 1.42
Diabetes mellitus 20.77 18.24 1.14 0.98 1.29
Degenerative joint disease 5.67 5.11 1.11 0.82 1.40
Malignant neoplasms 12.90 11.63 1.11 0.92 1.30
Disorders of lipid metabolism 34.44 31.32 1.10 0.98 1.22
Arterial hypertension 51.98 48.14 1.08 0.99 1.17
Deafness, hearing loss 8.19 7.87 1.04 0.82 1.27
Parkinson’s disease 1.66 1.71 0.97 0.50 1.44
Benign prostatic hypertrophy 15.81 16.41 0.96 0.81 1.11
Dementias 1.92 2.56 0.75 0.41 1.08
EDC: expanded diagnosis cluster.
(*) Standardised prevalence ratio.
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of risk factors must be taken into account [33].
We observed 89% more chronic liver diseases than
expected in a general population of this age and sex.
This association has been little described but a Japanese-
based study, targeting family medicine offices attended
by specialist physicians [35], reported an elevated preva-
lence of chronic liver disease, chronic hepatitis C, hep-
atic steatosis and alcoholic hepatitis. Another study [36]
similarly observed this association between liver disease
and COPD, after controlling for age, sex and smoking
habit. In addition, COPD has been described as hav-
ing a swifter progression in hepatitis C patients [37].
Although, the aetiopathogenic mechanisms of this
association are unclear, an interleukin-8 mediated
chronic inflammatory process is suspected as being
the cause [38].
Furthermore, 7% of COPD patients have osteoporosis,
with a frequency that is 10 times greater in women thanin men, and an observed prevalence that is higher than
expected for patients of their age and sex. Some studies
report patients with COPD as having a threefold risk of
presenting with osteoporosis [19,21]. Since a number of
studies have shown that inhaled corticoids have no effect
on bone density, other factors, such as reduced mobility,
smoking habit or adverse effects of other drugs, may be
the cause of this.
Anxiety and depression are frequent among patients
with COPD. In our study, 20% of patients presented
with these problems, with a frequency that was twice as
high in women as in men. In one review, prevalence var-
ied widely between some studies and others, due in part
to the measurement instrument used and type of patient
studied. Among stable patients, prevalence of depression
ranged from 10% to 42% and prevalence of anxiety from
10% to 19% [39]. Our data are in line with those pub-
lished. The causes for the increase in affective disorders
in these patients are uncertain but, in addition to the
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nicotine dependence may play an important role [40].
Six per cent of our patients had COPD and asthma,
with a frequency that was more than three times higher
in women than in men. This prevalence is lower than
that observed in population-based studies [41], a finding
probably explained by the same type of underdiagnosis
as that which affects COPD. This overlapping of diseases
in the same patient represents a diagnostic and thera-
peutic challenge for FPs [42,43].
This study suffers from some limitations: firstly, there are
those inherent in any retrospective design which uses
EMRs as its data source. As a data source, medical records
introduce biases stemming from under-registration and the
poor quality of the data recorded [44]. In an attempt to
solve this problem, physicians were selected according to
the quality of their records.
Another limitation derives from the case-definition
criterion used, i.e., the need for patients’ clinical histories
to show evidence of diagnosis of COPD, since FPs are
well known for making little use of spirometry and for
misclassifying COPD patients [45]. However, in view of
the fact that this was a chronic disease and of the longi-
tudinal nature of primary care, it is likely that underdiag-
nosis involved the milder forms of COPD [22,46] and
that misclassification was due to COPD being diagnosed
as asthma and vice-versa.
Conclusions
COPD is pathology with high sanitary, social and eco-
nomic impact. Patients suffering COPD present high co
morbidity associated to other pathologies of high impact
on healthcare services; as a consequence COPD patients
stratification should regard the comorbidity burden in
addition to the degree of obstruction.
The clinical practice guidelines that are in place are tar-
geted at isolated diseases and do not envisage the existence
of comorbidity. Moreover, the healthcare delivery models
based on diseases management offer a poor response to
comorbidity problem and tend to fragment the assistance
to the patient inciding negatively on healthcare services
[47]. In addition, the emerging healthcare model based on
telemonitoring and treatment “is going home” [48], and
providers of such care need to customise services involved
in following up and monitoring chronically ill patients in
their homes. Consequently, comorbidity poses a challenge
for the care of COPD patients, and so studies are needed
that will help specify these different patient profiles.
In view of the results of this study, there is a need for
improving the diagnosis of COPD in family practices,
there is a need for clinical practice guidelines to be
reviewed and rendered patient- rather than disease-
oriented [49]. Similarly there is a need to adapt patient
telemonitoring programmes and applications [48], aswell as care-delivery models in general, so that these can
adopt an integrated approach patient-centered, based on
longitudinal care and co-ordination.Ethics approval
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